The Rogel and Blondy Center for Pancreatic Cancer is a center of excellence in pancreatic cancer research, combining pioneering research with innovative clinical care and an array of clinical trials. Center co-director Marina Pasca di Magliano explains that the key to a robust research program and responsive care lies in collaboration.

A study from the University of Michigan Health Rogel Cancer Center furthers research that suggests the potential of developing new cancer treatments to target oncogenic transcription factors by indirectly affecting their ability to access enhancer DNA in chromatin.

A study finds giving a fatty acid inhibitor alongside chemotherapy could improve the treatment efficacy for patients with brain metastases from triple negative breast cancer

A team of researchers at the University of Michigan Health Rogel Cancer Center has designed a molecule that impairs signaling mediated by two key drivers of cancer therapy resistance.

Researchers from the University of Michigan Health Rogel Cancer Center have discovered a biomarker that could help identify which renal cancer patients have a higher risk of recurrence.

Researchers at the University of Michigan Health Rogel Cancer Center are one step closer to understanding how pediatric DIPG tumors work.

When white blood cells, meant to protect the body from infection, are overly activated, they eject their DNA into nets, further disrupting the immune system and making patients more likely to develop a potentially severe reaction to immunotherapy.

At-home test can detect tumor DNA fragments in urine samples, providing a non-invasive alternative to traditional blood-based biomarker tests

Findings from researchers at the University of Michigan Health Rogel Cancer Center, published in Cancer Discovery, show how a specific nucleotide metabolite called GTP controls responses to radiation and chemotherapy in an unexpected way.

Metabolism pathways make tumors sensitive or resistant to treatments. A collaborative group leverages these avenues to explore the growing foundation of new potential therapies

University of Michigan Rogel Cancer Center researchers are unraveling its nuances, advancing enabling technologies, advocating for patients and figuring out how to ethically integrate this technology into clinical care.

Early findings of two studies from the University of Michigan Rogel Cancer Center shed light on new ways to anticipate recurrence in HPV-positive head and neck cancer sooner. The papers, published in Cancer and Oral Oncology, offer clinical and technological perspectives on how to measure if recurrence is happening earlier than current blood tests allow, and provide a framework for a new, more sensitive blood test that could help in this monitoring.

Research from the University of Michigan Department of Neurosurgery and Rogel Cancer Center shows promising early results that a therapy combining cell-killing and immune-stimulating drugs are safe and effective in extending survival for patients with gliomas, a highly aggressive form of brain cancer.

A study from the University of Michigan Rogel Cancer Center uncovers a new mechanism to explain why some prostate tumors switch from a common, treatable form to a more rare and aggressive form of prostate cancer.

A study from clinicians and researchers at the University of Michigan Rogel Cancer Center reveals findings from over 800 clinical assays performed for kidney patients with MiTF family gene mutations.